THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q3 2018 13F Holders as of 30 Sep 2018

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
101.38%
Total 13F principal
$213,176,006
Principal change
+$7,012,300
Total reported market value
$216,921,563
Number of holders
29
Value change
+$7,886,593
Number of buys
11
Number of sells
16

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q3 2018

As of 30 Sep 2018, THERAVANCE INC - CORPORATE OBLIG was held by 29 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $213,176,006 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, ADVENT CAPITAL MANAGEMENT /DE/, CNH PARTNERS LLC, LAZARD ASSET MANAGEMENT LLC, CALAMOS ADVISORS LLC, OAKTREE CAPITAL MANAGEMENT LP, AMERIPRISE FINANCIAL INC, SSI INVESTMENT MANAGEMENT INC, BANK OF AMERICA CORP /DE/, and Allianz Asset Management GmbH. This page lists 29 institutional bondholders reporting positions for the Q3 2018 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.